CSPC Innovation Pharmaceutical Co Ltd Class A (300765) - Total Assets
Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) holds total assets worth CN¥6.21 Billion CNY (≈ $908.72 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of CSPC Innovation Pharmaceutical Co Ltd Cl to assess how comfortably operating cash covers total debt obligations.
CSPC Innovation Pharmaceutical Co Ltd Class A - Total Assets Trend (2014–2025)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. See 300765 book value for net asset value and shareholders' equity analysis.
CSPC Innovation Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2025)
CSPC Innovation Pharmaceutical Co Ltd Class A's total assets of CN¥6.21 Billion consist of 45.5% current assets and 54.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.3% |
| Accounts Receivable | CN¥704.16 Million | 11.2% |
| Inventory | CN¥497.80 Million | 7.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥218.85 Million | 3.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CSPC Innovation Pharmaceutical Co Ltd Cl market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC Innovation Pharmaceutical Co Ltd Class A's current assets represent 45.5% of total assets in 2025, a decrease from 60.0% in 2014.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, down from 16.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 6.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 11.2% of total assets.
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of CSPC Innovation Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Saputo Inc
TO:SAP
|
Canada | CA$13.61 Billion |
|
Orkla ASA
OL:ORK
|
Norway | Nkr88.70 Billion |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
Germany | €54.94 Billion |
|
Maple Leaf Foods Inc.
TO:MFI
|
Canada | CA$4.45 Billion |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
Mexico | MX$35.95 Billion |
|
Scandi Standard publ AB
ST:SCST
|
Sweden | Skr7.65 Billion |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
Greece | €219.80 Million |
|
Namchow Food Group (Shanghai) Co. Ltd.
SHG:605339
|
China | CN¥4.18 Billion |
CSPC Innovation Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.77 | 9.82 |
| Quick Ratio | 0.83 | 1.51 | 9.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-2.04 Million | CN¥1.24 Billion | CN¥1.93 Billion |
CSPC Innovation Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between CSPC Innovation Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.48 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | CN¥6.28 Billion |
| Market Capitalization | $7.47 Billion USD |
Valuation Analysis
Above Book Valuation: The market values CSPC Innovation Pharmaceutical Co Ltd Class A's assets above their book value (1.19x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: CSPC Innovation Pharmaceutical Co Ltd Class A's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual total assets of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.28 Billion ≈ $918.42 Million |
+4.22% |
| 2024-12-31 | CN¥6.02 Billion ≈ $881.22 Million |
-19.41% |
| 2023-12-31 | CN¥7.47 Billion ≈ $1.09 Billion |
+63.01% |
| 2022-12-31 | CN¥4.58 Billion ≈ $670.79 Million |
+22.53% |
| 2021-12-31 | CN¥3.74 Billion ≈ $547.46 Million |
+26.54% |
| 2020-12-31 | CN¥2.96 Billion ≈ $432.64 Million |
+3.65% |
| 2019-12-31 | CN¥2.85 Billion ≈ $417.39 Million |
+105.09% |
| 2018-12-31 | CN¥1.39 Billion ≈ $203.52 Million |
+23.18% |
| 2017-12-31 | CN¥1.13 Billion ≈ $165.22 Million |
+16.56% |
| 2016-12-31 | CN¥968.68 Million ≈ $141.75 Million |
+1.22% |
| 2015-12-31 | CN¥957.02 Million ≈ $140.04 Million |
+15.05% |
| 2014-12-31 | CN¥831.82 Million ≈ $121.72 Million |
-- |
About CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food product… Read more